<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T04:01:32Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:4303192" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:4303192</identifier>
        <datestamp>2015-01-23</datestamp>
        <setSpec>brcnres</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id>
              <journal-id journal-id-type="iso-abbrev">Breast Cancer Res</journal-id>
              <journal-title-group>
                <journal-title>Breast Cancer Research : BCR</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1465-5411</issn>
              <issn pub-type="epub">1465-542X</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC4303192</article-id>
              <article-id pub-id-type="pmcid">PMC4303192</article-id>
              <article-id pub-id-type="pmc-uid">4303192</article-id>
              <article-id pub-id-type="pmid">25385439</article-id>
              <article-id pub-id-type="pmid">25385439</article-id>
              <article-id pub-id-type="publisher-id">463</article-id>
              <article-id pub-id-type="doi">10.1186/s13058-014-0463-1</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Singh</surname>
                    <given-names>Baljit</given-names>
                  </name>
                  <address>
                    <email>baljit.singh@nyumc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Smith</surname>
                    <given-names>Julia A</given-names>
                  </name>
                  <address>
                    <email>julia.smith@nyumc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Axelrod</surname>
                    <given-names>Deborah M</given-names>
                  </name>
                  <address>
                    <email>deborah.axelrod@nyumc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Ameri</surname>
                    <given-names>Pietro</given-names>
                  </name>
                  <address>
                    <email>pietro.ameri@nyumc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Levitt</surname>
                    <given-names>Heather</given-names>
                  </name>
                  <address>
                    <email>heather.levitt@nyumc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Danoff</surname>
                    <given-names>Ann</given-names>
                  </name>
                  <address>
                    <email>ann.danoff@nyumc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Lesser</surname>
                    <given-names>Martin</given-names>
                  </name>
                  <address>
                    <email>marty@nshs.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>de Angelis</surname>
                    <given-names>Cristina</given-names>
                  </name>
                  <address>
                    <email>cristinadeangelis83@hotmail.it</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Illa-Bochaca</surname>
                    <given-names>Irineu</given-names>
                  </name>
                  <address>
                    <email>Irineu.bochaca@nyumc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Lubitz</surname>
                    <given-names>Sara</given-names>
                  </name>
                  <address>
                    <email>drlubitz@gmail.com</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Huberman</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <address>
                    <email>daniel.huberman@gmail.com</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Darvishian</surname>
                    <given-names>Farbod</given-names>
                  </name>
                  <address>
                    <email>farbod.darvishian@nyumc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes" deceased="no" equal-contrib="no">
                  <name>
                    <surname>Kleinberg</surname>
                    <given-names>David L</given-names>
                  </name>
                  <address>
                    <email>david.kleinberg@nyumc.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution>Department of Pathology, </institution><institution>New York University School of Medicine, </institution></institution-wrap>New York, 10016 NY USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution>Department of Medicine, Division of Oncology, </institution><institution>New York University School of Medicine, </institution></institution-wrap>New York, 10016 NY USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution>Department of Surgery, </institution><institution>New York University School of Medicine, </institution></institution-wrap>New York, 10016 NY USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8753</institution-id><institution-id institution-id-type="GRID">grid.137628.9</institution-id><institution>Department of Medicine, Division of Endocrinology and Bunnie Joan Sachs Laboratory, </institution><institution>New York University School of Medicine, </institution></institution-wrap>550 First Avenue, New York, 10016 NY USA </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0420 1184</institution-id><institution-id institution-id-type="GRID">grid.274295.f</institution-id><institution/><institution>Department of Veterans Affairs Medical Center, </institution></institution-wrap>New York, 10016 NY USA </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2151 3065</institution-id><institution-id institution-id-type="GRID">grid.5606.5</institution-id><institution>Department of Internal Medicine, </institution><institution>University of Genoa, </institution></institution-wrap>Genoa, 16132 Italy </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2168 3646</institution-id><institution-id institution-id-type="GRID">grid.416477.7</institution-id><institution>Feinstein Institute for Medical Research, </institution><institution>North Shore - LIJ Health System, </institution></institution-wrap>Manhasset, 11030 NY USA </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8796</institution-id><institution-id institution-id-type="GRID">grid.430387.b</institution-id><institution/><institution>Rutgers Robert Wood Johnson Medical School, </institution></institution-wrap>New Brunswick, 08901 NJ USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>11</day>
                <month>11</month>
                <year>2014</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>11</day>
                <month>11</month>
                <year>2014</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2014</year>
              </pub-date>
              <volume>16</volume>
              <elocation-id>463</elocation-id>
              <history>
                <date date-type="received">
                  <day>11</day>
                  <month>11</month>
                  <year>2013</year>
                </date>
                <date date-type="accepted">
                  <day>14</day>
                  <month>10</month>
                  <year>2014</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Singh et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
                <license license-type="open-access">
                  <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Introduction</title>
                  <p>Estrogen inhibition is effective in preventing breast cancer in only up to 50% of women with precancerous lesions and many experience side effects that are poorly tolerated. As insulin-like growth factor I (IGF-I) underlies both estrogen and progesterone actions and has other direct effects on mammary development and carcinogenesis, we hypothesized that IGF-I inhibition might provide a novel approach for breast cancer chemoprevention.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>In total, 13 women with core breast biopsies diagnostic of atypical hyperplasia (AH) were treated for 10 days with pasireotide, a somatostatin analog which uniquely inhibits IGF-I action in the mammary gland. They then had excision biopsies. 12 patients also had proliferative lesions and one a ductal carcinoma in situ (DCIS). Primary outcomes were changes in cell proliferation and apoptosis after treatment. Expression of estrogen receptor (ER), progesterone receptor (PR), and phosphorylated Insulin-like growth factor I receptor (IGF-1R), protein kinase B (AKT) and extracellular signal-regulated kinases 1/2 (ERK1/2) were also assessed. Core and excision biopsies from 14 untreated patients served as non-blinded controls. Hyperglycemia and other side effects were carefully monitored.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Pasireotide decreased proliferation and increased apoptosis in all AH (from 3.6 ± 2.6% to 1.3 ± 1.2% and from 0.3 ± 0.2% to 1.5 ± 1.6%, respectively) and proliferative lesions (from 3.8 ± 2.5% to 1.8 ± 1.8% and from 0.3 ± 0.2% to 1.3 ± 0.6%, respectively). The DCIS responded similarly. ER and PR were not affected by pasireotide, while IGF-1R, ERK1/2 and AKT phosphorylation decreased significantly. In contrast, tissue from untreated controls showed no change in cell proliferation or phosphorylation of IGF-1R, AKT or ERK 1/2. Mild to moderate hyperglycemia associated with reduced insulin levels was found. Glucose fell into the normal range after discontinuing treatment. Pasireotide was well tolerated and did not cause symptoms of estrogen deprivation.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>IGF-I inhibition by pasireotide, acting through the IGF-1R, was associated with decreased proliferation and increased apoptosis in pre-malignant breast lesions and one DCIS. Assuming hyperglycemia can be controlled, these data suggest that inhibiting the IGF-I pathway may prove an effective alternative for breast cancer chemoprevention.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p><ext-link ext-link-type="uri" xlink:href="http://www.NCT01372644">NCT01372644</ext-link> Trial date: July 1, 2007.</p>
                </sec>
                <sec>
                  <title>Electronic supplementary material</title>
                  <p>The online version of this article (doi:10.1186/s13058-014-0463-1) contains supplementary material, which is available to authorized users.</p>
                </sec>
              </abstract>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2014</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p>Breast cancer is one of the most frequently diagnosed tumors worldwide. Randomized controlled trials demonstrated the preventive effects of tamoxifen and raloxifene in women at increased risk [<xref ref-type="bibr" rid="CR1">1</xref>]-[<xref ref-type="bibr" rid="CR3">3</xref>]. These studies have led to the practice of employing selective estrogen receptor modulators (SERMs) for breast cancer chemoprevention. However, a number of side effects limit their use, including climacteric symptoms in premenopausal women, thromboembolic phenomena, and for tamoxifen, endometrial hyperplasia and carcinoma. The compliance rate with anti-estrogen therapy in the chemopreventive setting has been reported to be as low as 20% [<xref ref-type="bibr" rid="CR4">4</xref>]. Breast cancer can be prevented in up to 50% of patients with high- risk lesions. Therefore, targeted estrogen inhibition is only partially effective. Alternative more effective medical approaches are highly desirable.</p>
              <p>Insulin-like growth factor I (IGF-I) affects mammary development in at least two ways. It has an independent effect on ductal morphogenesis and is also essential for estrogen and progesterone action in the mammary gland [<xref ref-type="bibr" rid="CR5">5</xref>]-[<xref ref-type="bibr" rid="CR7">7</xref>]. Furthermore, IGF-I plays a pivotal role in the multi-step process that leads from normal breast tissue to hyperplasia and then carcinoma [<xref ref-type="bibr" rid="CR8">8</xref>]. Based on these actions, we hypothesized that IGF-I inhibition would prevent breast cancer development. Indeed, published [<xref ref-type="bibr" rid="CR9">9</xref>] and as yet unpublished data from our laboratory have shown that blockade of IGF-I action in the mammary gland prevents the development of premalignant mammary lesions in different mouse models [<xref ref-type="bibr" rid="CR9">9</xref>]-[<xref ref-type="bibr" rid="CR11">11</xref>]. In these experiments, we used a novel multi-ligand somatostatin analog, pasireotide, which not only inhibits growth hormone secretion from the pituitary and thereby, serum IGF-I, but also specifically targets IGF-I action within the mammary gland [<xref ref-type="bibr" rid="CR12">12</xref>]. To translate the findings in rodents to humans, we conducted the present study, aimed at assessing the effect of IGF-I inhibition with pasireotide on premalignant lesions of the breast. Treatment with pasireotide caused a decrease in cell proliferation and an increase in apoptosis in all cases evaluated. Based on these results, we conclude that IGF-I inhibition may represent a novel strategy to prevent breast cancer.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <sec id="Sec3">
                <title>Study setting</title>
                <p>This study was conducted at the Clinical Cancer Center, the Clinical Translational Science Institute, the Immunohistochemistry and Histopathology Cores, and the BioRepository Center of the New York University (NYU) School of Medicine, and at the Department of Veterans Affairs Medical Center, New York, NY in accordance with the Helsinki Declaration. It was approved by the Institutional Review Board (IRB) at the NYU School of Medicine, the NYU Cancer Center Protocol Review and Monitoring Committee (PRMC) and the Department of Defense; Human Research Protection Office (HRPO), Office of Research Protections (ORP), United States Army Medical Research and Materiel Command (USAMRMC), the United States Food and Drug Administration (FDA), Novartis Pharmaceuticals and the Veterans Administration Office of Research and Development and Human Subjects Committee. The clinical trial number was NCT01372644.</p>
              </sec>
              <sec id="Sec4">
                <title>Participants</title>
                <p>The trial included women who were diagnosed with atypical hyperplasia (AH) of the breast (atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia/lobular carcinoma <italic>in situ</italic> (ALH/LCIS)) by core biopsy of lesions discovered by mammography (mass, density, calcifications). To be eligible, participants had to be over 21 years of age, be otherwise healthy, and be accessible for follow up. Patients in whom invasive breast cancer coexisted with AH or who had received tamoxifen or other anti-estrogens within the previous 6 months were excluded. Women with abnormal fasting plasma glucose or a QT interval longer than 450 msec were also excluded. Fifteen patients were enrolled and 13 completed the trial (Figure <xref rid="Fig1" ref-type="fig">1</xref>). Written informed consent was obtained from all.<fig id="Fig1"><label>Figure 1</label><caption><p><bold>Trial profile.</bold> IGF, insulin-like growth factor; s.c., subcutaneous.</p></caption><graphic xlink:href="13058_2014_463_Fig1_HTML" id="d29e740"/></fig></p>
              </sec>
              <sec id="Sec5">
                <title>Procedures</title>
                <p>IGF-I inhibition was achieved by treatment with 600 μg pasireotide (Novartis, Basel, Switzerland) subcutaneously injected twice daily for ten days. The patients self-injected the medication according to the instructions received at study entrance. They were also trained to measure finger-stick glucose with an Ascensia Contour<sup>®</sup> glucometer (Bayer Health Care, Mishawaka, IN, USA) and to follow a low carbohydrate diet. The day before starting the treatment, participants underwent a baseline evaluation comprising a complete medical examination, basic blood tests, and measurement of fasting insulin, HbA1c, and IGF-I. During the 10-day treatment period, patients monitored fasting glucose by finger stick every day and also attended the study center between days 3 and 7 for additional safety assessment. Women who had fasting finger-stick glucose &gt;120 mg/dL were asked to monitor glucose four times a day. On the tenth day they underwent standard-of-care excision biopsies with pre-operative wire placement. Women who had glucose levels ≥110 mg/dL at the end of treatment were asked to continue to monitor finger-stick glucose until glucose was normalized. Follow-up assessments were done 7 to 9 days, 20 to 25 days, and 3 months after the last injection of pasireotide (coinciding with the day of surgery) (Figure <xref rid="Fig1" ref-type="fig">1</xref>).</p>
                <p>Both the core and excision biopsies were reviewed by a breast pathologist to confirm diagnosis. One patient who had ductal carcinoma in situ (DCIS) in addition to AH was inadvertently included in the trial. Twelve of thirteen patients also had various proliferative lesions (usual ductal hyperplasia, sclerosing adenosis, small ductal papilloma, radial scar). The effects of pasireotide on these lesions were also analyzed.</p>
              </sec>
              <sec id="Sec6">
                <title>Immunohistochemistry</title>
                <p>Proliferation and apoptosis in epithelial cells were assessed by comparing formalin-fixed paraffin-embedded tissue sections of the core and excision biopsies. To reduce the possibility of chance effects, we also determined proliferation in core and excision biopsies from non-blinded patients who were not treated. Blocks were retrieved from the BioRepository Center of the NYU School of Medicine.</p>
                <p>Proliferating cells were identified by immunohistochemistry for Ki67 [<xref ref-type="bibr" rid="CR9">9</xref>]. Slides were incubated with Novocastra rabbit polyclonal anti-Ki67 antibodies (Leica Biosystems, Newcastle Upon Tyne, UK) and horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary antibodies (Dako, Carpinteria, CA, USA) and a 3,3’-diaminobenzidine (DAB) solution (Vector Laboratories, Burlingame, CA, USA) were used to detect the bound primary antibodies. The latter were omitted in negative controls. Apoptosis was demonstrated by terminal deoxynucleotidyl transferase (TdT) dUTP nick end labeling (TUNEL) [<xref ref-type="bibr" rid="CR9">9</xref>]. This technique is based on the activity of the TdT enzyme, which labels the fragmented DNA of apoptotic cells for subsequent detection with a chromogenic reaction. In this study TUNEL was performed using the ApopTag<sup>®</sup> kit (EMD Millipore, Billerica, MA, USA). Negative control tissue samples were not incubated with TdT.</p>
                <p>The expression of estrogen receptor (ER) and progesterone receptor (PR) was also determined by immunohistochemistry with rabbit monoclonal primary antibodies (Thermo Fisher Scientific, Waltham, MA, USA). Biotinylated anti-rabbit secondary antibodies, followed by streptavidin-HRP conjugate and DAB, were used for detection. Stained sections were imaged on a light microscope with Nikon ACT-1 software. For each lesion, the percentage of Ki67-positive, TUNEL-positive, ER-positive, and PR-positive cells was counted out of a total of 200 epithelial cells.</p>
                <p>After completing the immunostaining for Ki67, ER, and PR and the TUNEL, there was good-quality tissue left for further staining in five cases only for phosphorylated AKT and ERK 1/2 and four cases for phosphorylated IGF-1R in both core and excision biopsies. Sections were stained for phosphorylated AKT (Ser473) and phosphorylated ERK 1/2 (Thr202/Tyr204) by using rabbit monoclonal primary antibodies (Cell Signaling Technologies, Danvers, MA, USA) and biotinylated anti-rabbit secondary antibodies, streptavidin-HRP, and DAB for detection. Phosphorylation of AKT and ERK 1/2 was also assessed in the control samples from untreated patients. As the intensity of the immunostaining for phosphorylated AKT and ERK1/2 was heterogeneous, an intensity score (from 0 to 3) and a percentage score were ascertained for each lesion. A final score was then calculated by applying the following formula:<disp-formula id="Equ1"><alternatives><mml:math id="M1" overflow="scroll"><mml:mfenced close=")" open="("><mml:mrow><mml:mtext mathvariant="normal">percentage</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">weakly</mml:mtext><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">stained</mml:mtext><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">cells</mml:mtext><mml:mspace width="0.25em"/><mml:mo>*</mml:mo><mml:mspace width="0.25em"/><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/><mml:mo>+</mml:mo><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="normal">percentage</mml:mi><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">of</mml:mtext><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">moderately</mml:mtext><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">stained</mml:mtext><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">cells</mml:mtext><mml:mspace width="0.25em"/><mml:mo>*</mml:mo><mml:mspace width="0.25em"/><mml:mn>2</mml:mn></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/><mml:mo>+</mml:mo><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mrow><mml:mtext mathvariant="normal">percentage</mml:mtext><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">strongly</mml:mtext><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">stained</mml:mtext><mml:mspace width="0.25em"/><mml:mtext mathvariant="normal">cells</mml:mtext><mml:mspace width="0.25em"/><mml:mo>*</mml:mo><mml:mspace width="0.25em"/><mml:mn>3</mml:mn></mml:mrow></mml:mfenced><mml:mtext>.</mml:mtext></mml:math><graphic xlink:href="13058_2014_463_Equa_HTML.gif" position="anchor"/></alternatives></disp-formula></p>
                <p>Immunofluorescence for phosphorylated IGF-1R was performed using rabbit anti p-IGF-1R (Y1161) (Abcam, Cambridge, MA, USA) as primary antibody and a secondary antibody obtained from Donkey anti rabbit Alexa 488 (Life technologies, Grand Island, NY, USA). To quantify the phosphorylated IGF-1R (Y1161) ten images per case, which included glandular tissue, were randomly imaged using 40× objective with 0.95 numerical aperture Zeiss Plan-Apochromat objective on a Zeiss Axionvert equipped with epifluorescence. Mean intensity was evaluated for each treatment on twelve-bit images using in-home developed macros for the open source platform Fiji-ImageJ (NIH, Bethesda, MD, USA).</p>
              </sec>
              <sec id="Sec7">
                <title>Statistical analysis</title>
                <p>Descriptive statistics are presented as mean and SD and changes from before (core biopsy) to after (excision biopsy) treatment as both the actual arithmetic difference and the percent change relative to pre-treatment. Relative percent change is the preferred statistic, because it is adjusted for the before-biopsy value (for example, a decrease in Ki-67 from 5% to 4% is a 1% arithmetic decrease, but a 20% relative decrease). The primary endpoints were the changes and relative changes in cell proliferation and apoptosis from the core to the excision biopsies. The evaluation of ER and PR status before and after treatment was the secondary pre-specified endpoint.</p>
                <p>Due to the small sample size, a non-parametric approach was taken and the Wilcoxon signed rank (WSR) test was used to analyze the study outcomes. The sign test was also used to determine whether directionality of change differed from chance. Analysis was conducted separately on proliferative lesions and AH lesions. Two pathologists blinded to patient status read the slides for Ki67 and apoptosis. After that, one left the institution and the remaining slides (PR, ER, phosphorylated AKT and ERK 1/2) were analyzed only by the other pathologist. The paired <italic>t</italic>-test and repeated-measures analysis of variance (ANOVA) were used to compare the scores for phosphorylated AKT and ERK 1/2 before and after treatment and pIGF-1R by fluorescence. Blood concentrations of glucose, insulin, and IGF-I across study visits, respectively were also analyzed. In a separate sub-study, we demonstrated excellent inter-rater agreement between two pathologists who, blinded to one another, evaluated Ki-67 in 12 treated patients and 23 controls.</p>
              </sec>
              <sec id="Sec8">
                <title>Role of the funding source</title>
                <p>Neither the funding source nor the provider of the medication had any role in the design or conduct of the study, or in the collection, analysis, and interpretation of the data. The corresponding author had full access to all data and had final responsibility for the decision to submit for publication.</p>
              </sec>
            </sec>
            <sec id="Sec9">
              <title>Results</title>
              <sec id="Sec10">
                <title>Patients</title>
                <p>All patients were Caucasian. Mean age was 55.9 ± 6.2 years. Four women had ADH, three had a combination of ADH and ALH/LCIS, five had ALH/LCIS, and one had ALH/LCIS and DCIS. Some AH lesions were entirely removed with the core biopsy. However, those cases had remaining areas of proliferative disease in both core and excision biopsies that permitted evaluation of the effects of pasireotide. In all, there were twelve proliferative lesions, five ALH/LCIS, one ADH, and one DCIS available for assessment of the study endpoints. Control samples from untreated patients included ten proliferative and five AH lesions from 14 women whose mean age was 49.8 ± 6.9 years.</p>
              </sec>
              <sec id="Sec11">
                <title>Effect on cell proliferation</title>
                <p>Compared with pre-treatment core biopsies, pasireotide caused a reduction in cell proliferation in all proliferative and AH lesions in the excision biopsies (WSR, <italic>P</italic> = 0.001 and <italic>P</italic> = 0.031 respectively) (Figure <xref rid="Fig2" ref-type="fig">2</xref>A). On average, Ki67-positive cells decreased by 66.5% in proliferative lesions and by 56.7% in areas of AH. Cell proliferation also decreased by 73.5% (from 3.4% to 0.9%) in the DCIS lesion (Figure <xref rid="Fig3" ref-type="fig">3</xref>B).<fig id="Fig2"><label>Figure 2</label><caption><p><bold>Effect of treatment with pasireotide on cell proliferation and apoptosis in pre-malignant lesions of the breast.</bold> Effects of pasireotide on proliferation rate as assessed by immunohistochemistry for Ki67 in 12 proliferative <bold>(A)</bold> and 6 atypical hyperplasia <bold>(B)</bold> Apoptosis, as assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), in 11 proliferative <bold>(C)</bold> and 6 atypical hyperplasia <bold>(D)</bold> lesions of the breast before and after 10 days of treatment with pasireotide.</p></caption><graphic xlink:href="13058_2014_463_Fig2_HTML" id="d29e922"/></fig><fig id="Fig3"><label>Figure 3</label><caption><p><bold>Representative images of proliferation (Ki67) and apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)) from patients treated with pasireotide.</bold> Representative examples showing Ki67 immunostaining of atypical hyperplasia <bold>(A)</bold> and one case of ductal carcinoma <italic>in situ</italic> (DCIS) <bold>(B)</bold> from pasireotide-treated patients (top panel). <bold>(C)</bold> TUNEL staining of an atypical lobular hyperplasia (ALH) lesion before and after treatment with pasireotide. Positive cells are brown. <bold>(D)</bold> A small increase in the number of apoptotic cells (arrows) was also observed after treatment in one case of DCIS.</p></caption><graphic xlink:href="13058_2014_463_Fig3_HTML" id="d29e948"/></fig></p>
                <p>The percentage of Ki67-positive cells decreased in six of the ten control proliferative lesions (sign test, <italic>P</italic> = 0.29) and overall it did not significantly vary between the core and excision biopsies (mean change -1.2 ± 7.5%; WSR, <italic>P</italic> = 0.54). Similarly a reduction in proliferation was observed in two out of five AH lesions from untreated patients (Figure <xref rid="Fig2" ref-type="fig">2</xref>B). These decreases were not significantly different from the hypothesis of random change (sign test, <italic>P</italic> = 1.00 and <italic>P</italic> = 0.77, respectively), nor was the mean percentage of Ki67-positive cells significantly different in core versus excision biopsies (1.1 ± 5.2%, WSR <italic>P</italic> = 0.44 for AH and -0.6 ± 16.1%, WSR <italic>P</italic> = 0.97 for DCIS), (Figure <xref rid="Fig3" ref-type="fig">3</xref>C-D). These results represent the work of pathologist BS.</p>
              </sec>
              <sec id="Sec12">
                <title>Effect on apoptosis</title>
                <p>An increase in apoptosis was found in all proliferative and AH lesions upon treatment with pasireotide (WSR, <italic>P</italic> = 0.001 and WSR, <italic>P</italic> = 0.031, respectively; Figure <xref rid="Fig4" ref-type="fig">4</xref>A-C), as well as in the DCIS (from 0.1% to 0.4%; Figure <xref rid="Fig4" ref-type="fig">4</xref>D).<fig id="Fig4"><label>Figure 4</label><caption><p><bold>Effect of pasireotide on the estrogen and progesterone receptor.</bold> No significant differences were observed in the levels of estrogen receptor (ER) <bold>(A)</bold> or progesterone receptor (PR) <bold>(B)</bold> before and after treating with pasireotide.</p></caption><graphic xlink:href="13058_2014_463_Fig4_HTML" id="d29e1009"/></fig></p>
              </sec>
              <sec id="Sec13">
                <title>Effects on ER and PR</title>
                <p>Pasireotide had no significant effect on ER or PR. Effects of pasireotide on ER and PR are shown in Table <xref rid="Tab1" ref-type="table">1</xref> and Figure <xref rid="Fig4" ref-type="fig">4</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p><bold>Changes in the expression of estrogen receptor (ER) and progesterone receptor (PR) following treatment with pasireotide</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Number</th><th>Change in percentage of positive cells</th><th><italic>P</italic> -value</th><th>Number of lesions in which the percentage of positive cells decreased</th><th><italic>P</italic> -value</th></tr></thead><tbody><tr><td><bold>Proliferative lesions</bold></td><td/><td/><td/><td/><td/></tr><tr><td>ER</td><td char="." align="char">9</td><td>–4.2 ± 9.9</td><td char="." align="char">0.13</td><td>7 (77.8%)</td><td char="." align="char">0.18</td></tr><tr><td>PR</td><td char="." align="char">7</td><td>–9.8 ± 30.7</td><td char="." align="char">0.81</td><td>3 (42.9%)</td><td char="." align="char">1.00</td></tr><tr><td><bold>Atypical hyperplasia</bold></td><td/><td/><td/><td/><td/></tr><tr><td>ER</td><td char="." align="char">5</td><td>–8.0 ± 15.0</td><td char="." align="char">0.31</td><td>2 (40%)</td><td char="." align="char">1.00</td></tr><tr><td>PR</td><td char="." align="char">4</td><td>–10.7 ± 54.3</td><td char="." align="char">0.88</td><td>2 (50%)</td><td char="." align="char">1.00</td></tr></tbody></table><table-wrap-foot><p>Differences in the percentage of positive cells in core versus excision biopsies are presented as mean ± SD.</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec14">
                <title>Mechanism of action of pasireotide</title>
                <p>We recently reported that pasireotide inhibited cell proliferation and increased apoptosis in a model of rat mammary hyperplasia induced by hGH + E<sub>2</sub> by blockade of the IGF-I receptor, as measured by a reduction in pIRS1 [<xref ref-type="bibr" rid="CR9">9</xref>]. To determine if pasireotide also worked through that mechanism in women with atypical hyperplasia we measured the effect of pasireotide on phospho IGF-1R expression, as measured by intensity of immunofluorescence, and found that it was significantly lowered in excision biopsies after treatment compared to pre-treatment core biopsies. Measurements in before and after core and excision biopsies in untreated patients served as controls (Figure <xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Figure 5</label><caption><p><bold>Effect of treatment with pasireotide on phospho insulin-like growth factor -1 receptor (IGF-1R).</bold> Effect of pasireotide on mean intensity of phospho IGF-1R by immunofluorescence in four patients with atypical hyperplasia before and after treatment with pasireotide <bold>(A)</bold> and five controls <bold>(B)</bold>. Representative sections from one of the patients before <bold>(C)</bold> and after treatment <bold>(D)</bold>. DAPI: 4',6-diamidino-2-phenylindole; n.s., not significant.</p></caption><graphic xlink:href="13058_2014_463_Fig5_HTML" id="d29e1200"/></fig></p>
                <p>Phosphorylated AKT and ERK 1/2 were also affected in five proliferative, two ALH/LCIS, and one ADH from five women. Both the number of positive cells and the intensity of the staining were lower in excision than in core biopsies (Figure <xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6"><label>Figure 6</label><caption><p><bold>Effect of treatment with pasireotide on phospho AKT and ERK1/2. (A)</bold> The mean intensity index was decreased by pasireotide from 42.5 ± 14 to 9.37 ± 3 after treatment as measured in eight patients. <bold>(B)</bold> Similar effects were observed with phospho ERK1/2 with a mean intensity index of 218 ± 29 before to 100 ± 18 after treatment, measured in six patients. Control tissues were not affected for p-AKT <bold>(C)</bold> or p-ERK 1/2 <bold>(D)</bold>.</p></caption><graphic xlink:href="13058_2014_463_Fig6_HTML" id="d29e1225"/></fig></p>
              </sec>
              <sec id="Sec15">
                <title>Effects on glucose, insulin, HgbA1c and IGF-I and side effects</title>
                <p>Among the 14 treated patients, 11 (78.6%) had grade 1 nausea and seven (50%) grade 1 diarrhea. Both adverse events were transient. Side effects of estrogen inhibitors, such as hot flashes, night sweats, decreased libido, and vaginal dryness, were not reported. Mean fasting finger-stick glucose rose from the baseline value of 97.8 ± 14.2 mg/dL to a peak of 133.2 ± 23.9 mg/dL (Figure <xref rid="Fig7" ref-type="fig">7</xref>). On average the highest glucose value was reached seven days after the first injection of pasireotide. One patient was withdrawn from the study after her postprandial capillary glycemia reached 226 mg/dL. Four out of the thirteen study participants had fasting finger-stick glucose values ≥110 mg/dL on the last day of treatment. Their mean glucose decreased from 162.8 ± 21.2 mg/dL to 100.5 ± 18.8 mg/dL in one day, and by three days after drug discontinuation it was 92.0 ± 16.2 mg/dL. An additional five patients also continued to monitor glucose after day 10. Overall, fasting glucose was 98.7 ± 13.4 mg/dL by day 13.<fig id="Fig7"><label>Figure 7</label><caption><p><bold>Effects of treatment with pasireotide on glucose, insulin, and insulin-like growth factor -1 (IGF-I). (A)</bold> Mean concentrations of plasma glucose and serum insulin during the 10-day treatment with pasireotide and the subsequent follow up. <bold>(B)</bold> Mean serum concentration of IGF-I before, at the end of treatment, and 90 days after treatment with pasireotide. Error bars are SDs in both graphs.</p></caption><graphic xlink:href="13058_2014_463_Fig7_HTML" id="d29e1247"/></fig></p>
                <p>Hyperglycemia was associated with a reduction in insulin levels, which returned to normal by day 30 to 35 (Figure <xref rid="Fig7" ref-type="fig">7</xref>). HbA1c concentrations were not affected by treatment (5.6 ± 0.4% at baseline and 5.6 ± 0.3% three months after stopping the drug). Serum IGF-I decreased in all patients, confirming adherence to treatment, although it remained within the age-specific normal range in 11 (84.6%). It returned to normal by three months (Figure <xref rid="Fig5" ref-type="fig">5</xref>B).</p>
              </sec>
            </sec>
            <sec id="Sec16">
              <title>Discussion</title>
              <p>In recent years a number of IGF-I inhibitors have been tested in the treatment of various carcinomas. Both antibodies to the IGF-I receptor and small molecule inhibitors of its tyrosine kinase activity have been employed, usually together with other anti-cancer drugs [<xref ref-type="bibr" rid="CR13">13</xref>]-[<xref ref-type="bibr" rid="CR17">17</xref>]. Efficacy has been mixed, at best. The results led Yee to liken IGF-I inhibition to `the baby or the bathwater’ [<xref ref-type="bibr" rid="CR18">18</xref>]. Those studies were largely carried out in patients with advanced solid tumors.</p>
              <p>We have approached IGF-I inhibition from a different vantage point. Studies from our laboratory show that growth hormone-induced IGF-I is essential for mammary development in mice and rats [<xref ref-type="bibr" rid="CR6">6</xref>],[<xref ref-type="bibr" rid="CR7">7</xref>], and that growth hormone (GH), or IGF-I absence or inhibition, block development [<xref ref-type="bibr" rid="CR12">12</xref>],[<xref ref-type="bibr" rid="CR19">19</xref>]. In addition, administration of GH plus physiological concentrations of estradiol was found to cause mammary hyperplasia in hypophysectomised, oophorectomized rats [<xref ref-type="bibr" rid="CR9">9</xref>] and pasireotide prevented it. Pasireotide is uniquely effective in inhibiting the action of IGF-I in the mammary gland. Like the older somatostatin analogs, octreotide and lanreotide, it reduces GH secretion from the pituitary gland, which results in decreased liver expression of IGF-I, and thereby reduced serum levels. By virtue of its broader somatostatin receptor affinity profile, however, pasireotide also potently inhibits IGF-I activity directly in the mammary gland, likely by stimulating the expression of IGF-I binding protein 5, which preferentially binds to IGF-I making it unavailable for its receptor [<xref ref-type="bibr" rid="CR12">12</xref>]. Although a side-by-side comparison of pasireotide with tamoxifen was not done, the experiments provided evidence that pasireotide was at least as, or possibly more, effective than tamoxifen in preventing hormone-induced hyperplasia [<xref ref-type="bibr" rid="CR9">9</xref>]. It should be pointed out that we did not measure IGF-2 because specimens became unavailable.</p>
              <p>Anti-estrogen chemoprevention in patients with atypical lesions significantly decreases development of carcinoma [<xref ref-type="bibr" rid="CR2">2</xref>]. In this study we tested IGF-I inhibition for breast cancer prevention in humans, by analyzing the effect of pasireotide on different types of precancerous lesions including proliferative lesions, atypical hyperplasia and also one case of ductal carcinoma <italic>in situ</italic>. Atypical hyperplasias are characterized by genetic alterations and gene expression profiles similar to those of invasive carcinomas [<xref ref-type="bibr" rid="CR20">20</xref>] and are associated with an increased risk for developing cancer [<xref ref-type="bibr" rid="CR21">21</xref>]. We postulated that earlier lesions such as atypical hyperplasia would maintain their responsiveness to IGF-I inhibition. This proof-of-principal trial used surrogate biological endpoints (proliferation and apoptosis) in patients with atypical breast lesions to test the efficacy of IGF-I inhibition. Indeed, pasireotide significantly decreased cell proliferation in proliferative lesions and AH during 10 days of treatment. Importantly, pasireotide also reduced the percentage of proliferating cells in one case of DCIS.</p>
              <p>Phase 1 studies typically do not include randomized placebo-controlled arms. To help confirm observations in the treated group we examined core and excision biopsies from 15 women with precancerous lesions of proliferative disease and atypical hyperplasia, who underwent excision biopsies as standard of care. They did not receive pasireotide between core and excision biopsies. There was no significant difference in proliferation from the hypothesis of random change between core and excision biopsies. Although the cell proliferation indices were low in both treated and untreated patients, the lack of a reduction in cell proliferation in the untreated patients in excision biopsies helps support the Ki67 results. Deregulated proliferation underlies the entire spectrum of precancerous breast lesions and it is also a main feature of established cancer [<xref ref-type="bibr" rid="CR22">22</xref>]. Therefore, IGF-I inhibition by means of pasireotide affected a key event in breast carcinogenesis. Decreased proliferation is also thought to be a main mechanism by which estrogen inhibitors may prevent the development and inhibit the progression of breast cancer. Although the effects of pasireotide and estrogen inhibitors on cell proliferation have not been compared directly, the magnitude of change in published reports suggests that the effect of estrogen inhibitors is similar to that of pasireotide [<xref ref-type="bibr" rid="CR23">23</xref>]-[<xref ref-type="bibr" rid="CR26">26</xref>].</p>
              <p>Recent reports indicate that analysis of ki67 can be highly variable between different readers and at different institutions [<xref ref-type="bibr" rid="CR27">27</xref>]. To determine whether our pathology collaborators also experienced reading variability, we had two of them (BS and FS) independently read before- and after-treatment slides for cell proliferation in 10 patients (mean age 54.8 ± 4.7 years) and 23 untreated controls (mean age: 54.5 ± 9.1 years). The inter-rater agreement was excellent,</p>
              <p>Pasireotide was also found to significantly increase apoptosis in proliferative lesions, AH, and in one case of DCIS. Apoptosis is particularly effective in eliminating aberrant cells which might play a role in cancer prevention. This effect may be secondary to the inhibition of IGF-I, which is anti-apoptotic [<xref ref-type="bibr" rid="CR8">8</xref>], but also to an IGF-I-independent activity of pasireotide, as activation of the somatostatin receptors has been shown to directly induce cell cycle arrest and apoptosis in other tissues [<xref ref-type="bibr" rid="CR28">28</xref>]. Tamoxifen is also pro-apoptotic in breast cancer cells, as well as in experimental tumors in rats [<xref ref-type="bibr" rid="CR29">29</xref>],[<xref ref-type="bibr" rid="CR30">30</xref>]. However, the effects of tamoxifen on apoptosis in women in prevention trials are not as well-documented, making comparison difficult [<xref ref-type="bibr" rid="CR25">25</xref>],[<xref ref-type="bibr" rid="CR31">31</xref>].</p>
              <p>These studies show that pasireotide directly blocks the IGF-I receptor activity, which in turn, prevents free IGF-I binding to the IGF-1R [<xref ref-type="bibr" rid="CR12">12</xref>]. It also increases IGF binding protein 5, which is thought to preferentially bind to local IGF-I more than to the IGF-1R [<xref ref-type="bibr" rid="CR9">9</xref>]. Whether this event occurs after blockade of the IGF-1R or is independent is not known. That reduction in phosphorylated AKT and ERK 1/2, which are main intracellular mediators of IGF-I downstream IGF-I pathway, may explain the decrease in cell proliferation and increase in apoptosis [<xref ref-type="bibr" rid="CR8">8</xref>],[<xref ref-type="bibr" rid="CR32">32</xref>]. Specific inhibitors of AKT and ERK are presently being evaluated for treatment of breast cancer [<xref ref-type="bibr" rid="CR32">32</xref>].</p>
              <p>Pasireotide is presently approved for treatment of Cushing’s disease with the caveat that it can cause hyperglycemia or diabetes, or worsen existing diabetes [<xref ref-type="bibr" rid="CR33">33</xref>]. The present trial provides evidence that the hyperglycemia of pasireotide is caused by a reduction in serum insulin, and another recent study found that the reduction of insulin is accompanied by a reduction in glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) [<xref ref-type="bibr" rid="CR34">34</xref>]. These effects are clearly more problematic in patients with Cushing’s disease or women with underlying diabetes than they would be in otherwise normal individuals.</p>
              <p>Minimal to moderate hyperglycemia would not pose a major risk to these patients during relatively short periods. In contrast, prolonged exposure might do so. Therefore, it would be important to prevent or lessen the impact of pasireotide on hyperglycemia. Possible approaches might include, altering the dose of pasireotide, adding glucagon-like peptide 1 agonists, or metformin [<xref ref-type="bibr" rid="CR35">35</xref>], and/or using pasireotide intermittently. Preclinical studies in <italic>Brca</italic>1-deficient mice have shown that intermittent administration of pasireotide maintains its inhibitory effect on cell proliferation for at least 3 weeks after discontinuing medication (as yet unpublished). Our trial provides evidence that hyperglycemia disappears rapidly on stopping pasireotide. Thus, hyperglycemia might be decreased by reducing exposure to medication. Pasireotide is also available in a once-a-month preparation. However, until further studies are carried out, and a means of dealing with hyperglycemia is established, it is premature to suggest the use of pasireotide for breast cancer prevention.</p>
            </sec>
            <sec id="Sec17">
              <title>Conclusion</title>
              <p>In conclusion, these results provide proof of principle that inhibiting the effect of IGF-I downstream of the IGF-I pathway with pasireotide causes a decrease in cell proliferation and an increase in apoptosis in precancerous breast lesions. Further trials might support the concept that IGF-I inhibition might serve as a chemoprevention tool for breast cancer, especially in patients unable to tolerate direct estrogen inhibition.</p>
            </sec>
            <sec id="Sec18">
              <title>Authors’ contributions</title>
              <p>BS helped conceive and design the study, read and analyzed pathology slides, worked with fellows and scientists, and participated in writing the manuscript. JAS and DMA helped conceive and design the study, played major roles in clinical and intellectual aspects of the study, recruited and oversaw treatment, safety and participation of patients, and critically reviewed and revised the manuscript. PA performed experiments, carried out and analyzed biochemical endpoints, helped draft the manuscript, and prepared tables and graphs. HL coordinated patient participation and organized fellows and clinicians throughout the study, obtained IND from the FDA, coordinated regulatory document submissions, helped with preparation of required technical and annual progress reports, and critically read and participated in the writing the manuscript. AD participated in design and writing of the study protocol, oversaw evaluation of patients’ hyperglycemia and other side effects, and critically reviewed and helped prepare the manuscript. ML performed statistical analysis for all aspects of the clinical trial, and prepared the statistical analysis section of the manuscript. CdA performed staining, prepared and maintained records of archived slides and prepared standards for blind analysis of slides, and prepared graphs and tables for the manuscript. II-B performed analysis of effects of pasireotide on phosphorylated IGF-I receptor, prepared slides and conceived the semiquantitative analysis for phosphorylation of AKT and ERK 1/2, and prepared tables, graphs and figures for the manuscript. SL monitored patients daily during and after the study for compliance and safety, analyzed the data, prepared regulatory documentation for submission to various ethics committees and helped draft and critically review the manuscript. DH analyzed data relating to glucose, insulin and IGF-I and prepared graphs and tables included in the manuscript, and critically reviewed it. FD joined the study group to determine agreement between pathologists on reading Ki67, and critically reviewed the manuscript, and helped revise the pathology section. DLK, Principal Investigator, conceived the project and was responsible for the accuracy and integrity of data and for patient safety, and oversaw all aspects of the study including drafting the grant, protocol, and manuscript. All authors have read and approved the final version of this manuscript.</p>
            </sec>
          </body>
          <back>
            <app-group>
              <app id="App1">
                <sec id="Sec19">
                  <title>Authors’ original submitted files for images</title>
                  <p>Below are the links to the authors’ original submitted files for images.<media position="anchor" xlink:href="13058_2014_463_MOESM1_ESM.gif" id="MOESM1"><caption><p>Authors’ original file for figure 1</p></caption></media><media position="anchor" xlink:href="13058_2014_463_MOESM2_ESM.gif" id="MOESM2"><caption><p>Authors’ original file for figure 2</p></caption></media><media position="anchor" xlink:href="13058_2014_463_MOESM3_ESM.gif" id="MOESM3"><caption><p>Authors’ original file for figure 3</p></caption></media><media position="anchor" xlink:href="13058_2014_463_MOESM4_ESM.gif" id="MOESM4"><caption><p>Authors’ original file for figure 4</p></caption></media><media position="anchor" xlink:href="13058_2014_463_MOESM5_ESM.gif" id="MOESM5"><caption><p>Authors’ original file for figure 5</p></caption></media><media position="anchor" xlink:href="13058_2014_463_MOESM6_ESM.gif" id="MOESM6"><caption><p>Authors’ original file for figure 6</p></caption></media><media position="anchor" xlink:href="13058_2014_463_MOESM7_ESM.gif" id="MOESM7"><caption><p>Authors’ original file for figure 7</p></caption></media></p>
                </sec>
              </app>
            </app-group>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>ADH</term>
                  <def>
                    <p>atypical ductal hyperplasia</p>
                  </def>
                </def-item>
                <def-item>
                  <term>AH</term>
                  <def>
                    <p>atypical hyperplasia</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ALH</term>
                  <def>
                    <p>atypical lobular hyperplasia</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ANOVA</term>
                  <def>
                    <p>analysis of variance</p>
                  </def>
                </def-item>
                <def-item>
                  <term><italic>Brca</italic>1</term>
                  <def>
                    <p>breast cancer suppressor gene called breast cancer 1, early onset</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DAB</term>
                  <def>
                    <p>3, 3׳-diaminobenzidine</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DCIS</term>
                  <def>
                    <p>ductal carcinoma <italic>in situ</italic></p>
                  </def>
                </def-item>
                <def-item>
                  <term>dUTP</term>
                  <def>
                    <p>deoxyuridine triphosphate</p>
                  </def>
                </def-item>
                <def-item>
                  <term>E<sub>2</sub></term>
                  <def>
                    <p>estrogen</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ER</term>
                  <def>
                    <p>estrogen receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FDA</term>
                  <def>
                    <p>Food and Drug Administration</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GH/hGH</term>
                  <def>
                    <p>growth hormone/human growth hormone</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GIP</term>
                  <def>
                    <p>glucose-dependent insulinotropic peptide</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GLP-1</term>
                  <def>
                    <p>glucagon-like peptide-1</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HbA1c</term>
                  <def>
                    <p>hemoglobin A1c</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HRP</term>
                  <def>
                    <p>horseradish peroxidase</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HRPO</term>
                  <def>
                    <p>Human Research Protection Office</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IGF</term>
                  <def>
                    <p>insulin-like growth factor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IGF-IR</term>
                  <def>
                    <p>insulin-like growth factor I receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IND</term>
                  <def>
                    <p>investigational new drug</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IRB</term>
                  <def>
                    <p>Institutional Review Board</p>
                  </def>
                </def-item>
                <def-item>
                  <term>Ki67</term>
                  <def>
                    <p>immunostain to identify cell proliferation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LCIS</term>
                  <def>
                    <p>lobular carcinoma <italic>in situ</italic></p>
                  </def>
                </def-item>
                <def-item>
                  <term>NIH</term>
                  <def>
                    <p>National Institutes of Health</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NYU</term>
                  <def>
                    <p>New York University</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ORP</term>
                  <def>
                    <p>Office of Research Protections</p>
                  </def>
                </def-item>
                <def-item>
                  <term>p-IGF-1R</term>
                  <def>
                    <p>phosphorylated IGF-I receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>pIRS1</term>
                  <def>
                    <p>phosphorylated insulin receptor substrate</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PR</term>
                  <def>
                    <p>progesterone receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PRMC</term>
                  <def>
                    <p>Protocol Review and Monitoring Committee</p>
                  </def>
                </def-item>
                <def-item>
                  <term>SERM</term>
                  <def>
                    <p>selective estrogen receptor modulator</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TdT</term>
                  <def>
                    <p>terminal deoxynucleotidyl transferase</p>
                  </def>
                </def-item>
                <def-item>
                  <term>USAMRMC</term>
                  <def>
                    <p>United States Army Medical Research and Materiel Command</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TUNEL</term>
                  <def>
                    <p>apoptosis</p>
                  </def>
                </def-item>
                <def-item>
                  <term>WSR</term>
                  <def>
                    <p>Wilcoxon signed rank</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Electronic supplementary material</bold>
                </p>
                <p>The online version of this article (doi:10.1186/s13058-014-0463-1) contains supplementary material, which is available to authorized users.</p>
              </fn>
              <fn>
                <p>
                  <bold>Competing interests</bold>
                </p>
                <p>DLK: NYU has applied for patents related to this work. DLK did not analyze slides from which results were determined in order to avoid potential bias. The other authors have no competing interests to declare.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We thank Dr Weifeng Ruan for staining slides for Ki67 and TUNEL, and reading some of the results in collaboration with Dr Singh. We are grateful to Drs Katalin Frisch and Malgorzata Teklinski for participating in patient care and protocol development. This study was funded by the USA Department of Defense Breast Cancer Research Program Synergistic Idea Award W81XWH-07-1-0488, grant number BC061512. The part of the study carried out at the Clinical Translational Science Institute of the NYU School of Medicine was supported by grant UL1 TR000038 from the National Center for the Advancement of Translational Science (NCATS), National Institutes of Health, USA. The Immunohistochemistry and Histopathology Cores were supported in part by grant 5P30CA016087-32 from the National Cancer Institute, USA. The BioRepository Center was supported in part by grant UL1TR000038 from the National Center for Research Resources, National Institutes of Health, USA, and grant 5P30CA016087-32 from the National Cancer Institute, USA. Part of the analysis was carried out at the New York Harbor Health Care System, Veterans Administration Hospital. Novartis (Basel, Switzerland) provided pasireotide.</p>
            </ack>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nelson</surname>
                      <given-names>HD</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Griffin</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Fu</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force</article-title>
                  <source>Ann Intern Med</source>
                  <year>2013</year>
                  <volume>158</volume>
                  <fpage>604</fpage>
                  <lpage>614</lpage>
                  <pub-id pub-id-type="doi">10.7326/0003-4819-158-8-201304160-00005</pub-id>
                  <?supplied-pmid 23588749?>
                  <pub-id pub-id-type="pmid">23588749</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fisher</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Costantino</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Wickerham</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Redmond</surname>
                      <given-names>CK</given-names>
                    </name>
                    <name>
                      <surname>Kavanah</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cronin</surname>
                      <given-names>WM</given-names>
                    </name>
                    <name>
                      <surname>Vogel</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Robidoux</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Dimitrov</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Atkins</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Daly</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wieand</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tan-Chiu</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Ford</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Wolmark</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>1998</year>
                  <volume>90</volume>
                  <fpage>1371</fpage>
                  <lpage>1388</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/90.18.1371</pub-id>
                  <?supplied-pmid 9747868?>
                  <pub-id pub-id-type="pmid">9747868</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cummings</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Eckert</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Krueger</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Grady</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Powles</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Cauley</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Norton</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Nickelsen</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Bjarnason</surname>
                      <given-names>NH</given-names>
                    </name>
                    <name>
                      <surname>Morrow</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Lippman</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Black</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Glusman</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Costa</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Jordan</surname>
                      <given-names>VC</given-names>
                    </name>
                  </person-group>
                  <article-title>The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation</article-title>
                  <source>JAMA</source>
                  <year>1999</year>
                  <volume>281</volume>
                  <fpage>2189</fpage>
                  <lpage>2197</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.281.23.2189</pub-id>
                  <?supplied-pmid 10376571?>
                  <pub-id pub-id-type="pmid">10376571</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coopey</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Mazzola</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Buckley</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Sharko</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Belli</surname>
                      <given-names>AK</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Polubriaginof</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Parmigiani</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Garber</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>BL</given-names>
                    </name>
                    <name>
                      <surname>Gadd</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Specht</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Guidi</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Roche</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Hughes</surname>
                      <given-names>KS</given-names>
                    </name>
                  </person-group>
                  <article-title>The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions</article-title>
                  <source>Breast Cancer Res Treat</source>
                  <year>2012</year>
                  <volume>136</volume>
                  <fpage>627</fpage>
                  <lpage>633</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10549-012-2318-8</pub-id>
                  <?supplied-pmid 23117858?>
                  <pub-id pub-id-type="pmid">23117858</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ruan</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Catanese</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Wieczorek</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Feldman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kleinberg</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid</article-title>
                  <source>Endocrinology</source>
                  <year>1995</year>
                  <volume>136</volume>
                  <fpage>1296</fpage>
                  <lpage>1302</lpage>
                  <pub-id pub-id-type="doi">10.1210/endo.136.3.7867584</pub-id>
                  <?supplied-pmid 7867584?>
                  <pub-id pub-id-type="pmid">7867584</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ruan</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Monaco</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Kleinberg</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action</article-title>
                  <source>Endocrinology</source>
                  <year>2005</year>
                  <volume>146</volume>
                  <fpage>1170</fpage>
                  <lpage>1178</lpage>
                  <pub-id pub-id-type="doi">10.1210/en.2004-1360</pub-id>
                  <?supplied-pmid 15604210?>
                  <pub-id pub-id-type="pmid">15604210</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ruan</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Kleinberg</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development</article-title>
                  <source>Endocrinology</source>
                  <year>1999</year>
                  <volume>140</volume>
                  <fpage>5075</fpage>
                  <lpage>5081</lpage>
                  <pub-id pub-id-type="doi">10.1210/endo.140.11.7095</pub-id>
                  <?supplied-pmid 10537134?>
                  <pub-id pub-id-type="pmid">10537134</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kleinberg</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Wood</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Furth</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>AV</given-names>
                    </name>
                  </person-group>
                  <article-title>Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions</article-title>
                  <source>Endocr Rev</source>
                  <year>2009</year>
                  <volume>30</volume>
                  <fpage>51</fpage>
                  <lpage>74</lpage>
                  <pub-id pub-id-type="doi">10.1210/er.2008-0022</pub-id>
                  <?supplied-pmid 19075184?>
                  <pub-id pub-id-type="pmid">19075184</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kleinberg</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Ameri</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Pasireotide, an IGF-I action inhibitor, prevents growth hormone and estradiol-induced mammary hyperplasia</article-title>
                  <source>Pituitary</source>
                  <year>2011</year>
                  <volume>14</volume>
                  <fpage>44</fpage>
                  <lpage>52</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11102-010-0257-0</pub-id>
                  <?supplied-pmid 20890664?>
                  <pub-id pub-id-type="pmid">20890664</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carboni</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Hadsell</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Rowley</surname>
                      <given-names>BR</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>FY</given-names>
                    </name>
                    <name>
                      <surname>Bol</surname>
                      <given-names>DK</given-names>
                    </name>
                    <name>
                      <surname>Camuso</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Gottardis</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Greer</surname>
                      <given-names>AF</given-names>
                    </name>
                    <name>
                      <surname>Ho</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Hurlburt</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Saulnier</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Velaparthi</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Wen</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Westhouse</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Wittman</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zimmermann</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Rupnow</surname>
                      <given-names>BA</given-names>
                    </name>
                    <name>
                      <surname>Wong</surname>
                      <given-names>TW</given-names>
                    </name>
                  </person-group>
                  <article-title>Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor</article-title>
                  <source>Cancer Res</source>
                  <year>2005</year>
                  <volume>65</volume>
                  <fpage>3781</fpage>
                  <lpage>3787</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4602</pub-id>
                  <?supplied-pmid 15867374?>
                  <pub-id pub-id-type="pmid">15867374</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hadsell</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Bonnette</surname>
                      <given-names>SG</given-names>
                    </name>
                  </person-group>
                  <article-title>IGF and insulin action in the mammary gland: lessons from transgenic and knockout models</article-title>
                  <source>J Mammary Gland Biol Neoplasia</source>
                  <year>2000</year>
                  <volume>5</volume>
                  <fpage>19</fpage>
                  <lpage>30</lpage>
                  <pub-id pub-id-type="doi">10.1023/A:1009559014703</pub-id>
                  <?supplied-pmid 10791765?>
                  <pub-id pub-id-type="pmid">10791765</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ruan</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Fahlbusch</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Clemmons</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Monaco</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Walden</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Silva</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Schmid</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Kleinberg</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?</article-title>
                  <source>Mol Endocrinol</source>
                  <year>2006</year>
                  <volume>20</volume>
                  <fpage>426</fpage>
                  <lpage>436</lpage>
                  <pub-id pub-id-type="doi">10.1210/me.2005-0283</pub-id>
                  <?supplied-pmid 16223973?>
                  <pub-id pub-id-type="pmid">16223973</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tap</surname>
                      <given-names>WD</given-names>
                    </name>
                    <name>
                      <surname>Demetri</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Barnette</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Desai</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kavan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Tozer</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Benedetto</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Friberg</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>McCaffery</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Leitch</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Badola</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Zhu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tolcher</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors</article-title>
                  <source>J Clin Oncol</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <fpage>1849</fpage>
                  <lpage>1856</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2011.37.2359</pub-id>
                  <?supplied-pmid 22508822?>
                  <pub-id pub-id-type="pmid">22508822</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Yee</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeting insulin and insulin-like growth factor signaling in breast cancer</article-title>
                  <source>J Mammary Gland Biol Neoplasia</source>
                  <year>2012</year>
                  <volume>17</volume>
                  <fpage>251</fpage>
                  <lpage>261</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10911-012-9268-y</pub-id>
                  <?supplied-pmid 23054135?>
                  <pub-id pub-id-type="pmid">23054135</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bruchim</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Werner</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeting IGF-1 signaling pathways in gynecologic malignancies</article-title>
                  <source>Expert Opin Ther Targets</source>
                  <year>2013</year>
                  <volume>17</volume>
                  <fpage>307</fpage>
                  <lpage>320</lpage>
                  <pub-id pub-id-type="doi">10.1517/14728222.2013.749863</pub-id>
                  <?supplied-pmid 23294364?>
                  <pub-id pub-id-type="pmid">23294364</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murakami</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Doi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Yamamoto</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Watanabe</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Boku</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Fuse</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Yoshino</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Ohtsu</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Otani</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Shibayama</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Takubo</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Loh</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors</article-title>
                  <source>Cancer Chemother Pharmacol</source>
                  <year>2012</year>
                  <volume>70</volume>
                  <fpage>407</fpage>
                  <lpage>414</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00280-012-1924-9</pub-id>
                  <?supplied-pmid 22810805?>
                  <pub-id pub-id-type="pmid">22810805</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McKian</surname>
                      <given-names>KP</given-names>
                    </name>
                    <name>
                      <surname>Haluska</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Cixutumumab</article-title>
                  <source>Expert Opin Investig Drugs</source>
                  <year>2009</year>
                  <volume>18</volume>
                  <fpage>1025</fpage>
                  <lpage>1033</lpage>
                  <pub-id pub-id-type="doi">10.1517/13543780903055049</pub-id>
                  <?supplied-pmid 19548856?>
                  <pub-id pub-id-type="pmid">19548856</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yee</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Insulin-like growth factor receptor inhibitors: baby or the bathwater?</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2012</year>
                  <volume>104</volume>
                  <fpage>975</fpage>
                  <lpage>981</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/djs258</pub-id>
                  <?supplied-pmid 22761272?>
                  <pub-id pub-id-type="pmid">22761272</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kleinberg</surname>
                      <given-names>DL</given-names>
                    </name>
                  </person-group>
                  <article-title>Early mammary development: Growth hormone and IGF-1</article-title>
                  <source>J Mammary Gland Biol Neoplasia</source>
                  <year>1997</year>
                  <volume>2</volume>
                  <fpage>49</fpage>
                  <lpage>57</lpage>
                  <pub-id pub-id-type="doi">10.1023/A:1026373513521</pub-id>
                  <?supplied-pmid 10887519?>
                  <pub-id pub-id-type="pmid">10887519</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ma</surname>
                      <given-names>XJ</given-names>
                    </name>
                    <name>
                      <surname>Salunga</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Tuggle</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Gaudet</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Enright</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>McQuary</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Payette</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Pistone</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Stecker</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Zhou</surname>
                      <given-names>YX</given-names>
                    </name>
                    <name>
                      <surname>Varnholt</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Gadd</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Chatfield</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kessler</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Baer</surname>
                      <given-names>TM</given-names>
                    </name>
                    <name>
                      <surname>Erlander</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Sgroi</surname>
                      <given-names>DC</given-names>
                    </name>
                  </person-group>
                  <article-title>Gene expression profiles of human breast cancer progression</article-title>
                  <source>Proc Natl Acad Sci U S A</source>
                  <year>2003</year>
                  <volume>100</volume>
                  <fpage>5974</fpage>
                  <lpage>5979</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.0931261100</pub-id>
                  <?supplied-pmid 12714683?>
                  <pub-id pub-id-type="pmid">12714683</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hartmann</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Sellers</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Frost</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Lingle</surname>
                      <given-names>WL</given-names>
                    </name>
                    <name>
                      <surname>Degnim</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Ghosh</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Vierkant</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Maloney</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Pankratz</surname>
                      <given-names>VS</given-names>
                    </name>
                    <name>
                      <surname>Hillman</surname>
                      <given-names>DW</given-names>
                    </name>
                    <name>
                      <surname>Suman</surname>
                      <given-names>VJ</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Blake</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Tisty</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Vachon</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Melton</surname>
                      <given-names>LJ</given-names>
                      <suffix>3rd</suffix>
                    </name>
                    <name>
                      <surname>Visscher</surname>
                      <given-names>DW</given-names>
                    </name>
                  </person-group>
                  <article-title>Benign breast disease and the risk of breast cancer</article-title>
                  <source>N Engl J Med</source>
                  <year>2005</year>
                  <volume>353</volume>
                  <fpage>229</fpage>
                  <lpage>237</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa044383</pub-id>
                  <?supplied-pmid 16034008?>
                  <pub-id pub-id-type="pmid">16034008</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cichon</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Degnim</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Visscher</surname>
                      <given-names>DW</given-names>
                    </name>
                    <name>
                      <surname>Radisky</surname>
                      <given-names>DC</given-names>
                    </name>
                  </person-group>
                  <article-title>Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer</article-title>
                  <source>J Mammary Gland Biol Neoplasia</source>
                  <year>2010</year>
                  <volume>15</volume>
                  <fpage>389</fpage>
                  <lpage>397</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10911-010-9195-8</pub-id>
                  <?supplied-pmid 21161341?>
                  <pub-id pub-id-type="pmid">21161341</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Uehara</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Nazario</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Rodrigues de Lima</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Simoes</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Juliano</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Gebrim</surname>
                      <given-names>LH</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of tamoxifen on the breast in the luteal phase of the menstrual cycle</article-title>
                  <source>Int J Gynaecol Obstet</source>
                  <year>1998</year>
                  <volume>62</volume>
                  <fpage>77</fpage>
                  <lpage>82</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0020-7292(98)00050-2</pub-id>
                  <?supplied-pmid 9722130?>
                  <pub-id pub-id-type="pmid">9722130</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bernardes</surname>
                      <given-names>JR</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Seixas</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Lima</surname>
                      <given-names>GR</given-names>
                    </name>
                    <name>
                      <surname>Marinho</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Gebrim</surname>
                      <given-names>LH</given-names>
                    </name>
                  </person-group>
                  <article-title>The effect of tamoxifen on PCNA expression in fibroadenomas</article-title>
                  <source>Breast J</source>
                  <year>2003</year>
                  <volume>9</volume>
                  <fpage>302</fpage>
                  <lpage>306</lpage>
                  <pub-id pub-id-type="doi">10.1046/j.1524-4741.2003.09410.x</pub-id>
                  <?supplied-pmid 12846865?>
                  <pub-id pub-id-type="pmid">12846865</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dowsett</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bundred</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Decensi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sainsbury</surname>
                      <given-names>RC</given-names>
                    </name>
                    <name>
                      <surname>Lu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Hills</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>FJ</given-names>
                    </name>
                    <name>
                      <surname>Veronesi</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>O'Brien</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Muchmore</surname>
                      <given-names>DB</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients</article-title>
                  <source>Cancer Epidemiol Biomarkers Prev</source>
                  <year>2001</year>
                  <volume>10</volume>
                  <fpage>961</fpage>
                  <lpage>966</lpage>
                  <?supplied-pmid 11535548?>
                  <pub-id pub-id-type="pmid">11535548</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Iwata</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Masuda</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Sagara</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Kinoshita</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Nakamura</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Yanagita</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Nishimura</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Iwase</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Kamigaki</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Takei</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Tsuda</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Hayashi</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Noguchi</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer</article-title>
                  <source>Cancer</source>
                  <year>2013</year>
                  <volume>119</volume>
                  <fpage>704</fpage>
                  <lpage>713</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.27818</pub-id>
                  <?supplied-pmid 22972694?>
                  <pub-id pub-id-type="pmid">22972694</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Polley</surname>
                      <given-names>MY</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>McShane</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Gao</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hugh</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Mastropasqua</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Viale</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Zabaglo</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Penault-Llorca</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Bartlett</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Gown</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Symmans</surname>
                      <given-names>WF</given-names>
                    </name>
                    <name>
                      <surname>Piper</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Mehl</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Enos</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Hayes</surname>
                      <given-names>DF</given-names>
                    </name>
                    <name>
                      <surname>Dowsett</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Nielsen</surname>
                      <given-names>TO</given-names>
                    </name>
                  </person-group>
                  <article-title>An international Ki67 reproducibility study</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2013</year>
                  <volume>105</volume>
                  <fpage>1897</fpage>
                  <lpage>1906</lpage>
                  <pub-id pub-id-type="doi">10.1093/jnci/djt306</pub-id>
                  <?supplied-pmid 24203987?>
                  <pub-id pub-id-type="pmid">24203987</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Theodoropoulou</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Laupheimer</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Paez-Pereda</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Erneux</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Florio</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Pagotto</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Stalla</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Octreotide, a Somatostatin Analogue, mediates its Antiproliferative Action in Pituitary Tumor Cells by Altering Phosphatidylinositol 3-Kinase Signaling and Inducing Zac1 Expression</article-title>
                  <source>Cancer Res</source>
                  <year>2006</year>
                  <volume>66</volume>
                  <fpage>1576</fpage>
                  <lpage>1582</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1189</pub-id>
                  <?supplied-pmid 16452215?>
                  <pub-id pub-id-type="pmid">16452215</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Christov</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Ikui</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Shilkaitis</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Green</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Yao</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>You</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Grubbs</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Steele</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Lubet</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Weinstein</surname>
                      <given-names>IB</given-names>
                    </name>
                  </person-group>
                  <article-title>Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors</article-title>
                  <source>Breast Cancer Res Treat</source>
                  <year>2003</year>
                  <volume>77</volume>
                  <fpage>253</fpage>
                  <lpage>264</lpage>
                  <pub-id pub-id-type="doi">10.1023/A:1021804121171</pub-id>
                  <?supplied-pmid 12602925?>
                  <pub-id pub-id-type="pmid">12602925</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Kimijima</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Onda</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kanno</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sato</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Watanabe</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Tsuchiya</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Abe</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Takenoshita</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels</article-title>
                  <source>Clin Cancer Res</source>
                  <year>1999</year>
                  <volume>5</volume>
                  <fpage>2971</fpage>
                  <lpage>2977</lpage>
                  <?supplied-pmid 10537367?>
                  <pub-id pub-id-type="pmid">10537367</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Farczadi</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kaszas</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Baki</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Szende</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment</article-title>
                  <source>Neoplasma</source>
                  <year>2002</year>
                  <volume>49</volume>
                  <fpage>101</fpage>
                  <lpage>103</lpage>
                  <?supplied-pmid 12088100?>
                  <pub-id pub-id-type="pmid">12088100</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alvarez</surname>
                      <given-names>RH</given-names>
                    </name>
                    <name>
                      <surname>Valero</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Hortobagyi</surname>
                      <given-names>GN</given-names>
                    </name>
                  </person-group>
                  <article-title>Emerging targeted therapies for breast cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2010</year>
                  <volume>28</volume>
                  <fpage>3366</fpage>
                  <lpage>3379</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2009.25.4011</pub-id>
                  <?supplied-pmid 20530283?>
                  <pub-id pub-id-type="pmid">20530283</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Colao</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Petersenn</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Newell-Price</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Findling</surname>
                      <given-names>JW</given-names>
                    </name>
                    <name>
                      <surname>Gu</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Maldonado</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schoenherr</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Mills</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Salgado</surname>
                      <given-names>LR</given-names>
                    </name>
                    <name>
                      <surname>Biller</surname>
                      <given-names>BM</given-names>
                    </name>
                  </person-group>
                  <article-title>A 12-month phase 3 study of pasireotide in Cushing’s disease</article-title>
                  <source>N Engl J Med</source>
                  <year>2012</year>
                  <volume>366</volume>
                  <fpage>914</fpage>
                  <lpage>924</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1105743</pub-id>
                  <?supplied-pmid 22397653?>
                  <pub-id pub-id-type="pmid">22397653</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Henry</surname>
                      <given-names>RRMS</given-names>
                    </name>
                    <name>
                      <surname>Wetli-Hermosillo</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Ligueros-Saylan</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Chenji</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Golor</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Mechanism and Management of Hyperglycemia Associated with Pasireotide: Results from Studies in Healthy volunteers</article-title>
                  <source>Endocr Rev</source>
                  <year>2011</year>
                  <volume>32</volume>
                  <fpage>3</fpage>
                  <lpage>274</lpage>
                  <pub-id pub-id-type="doi">10.1210/er.2009-0043</pub-id>
                  <pub-id pub-id-type="pmid">20729338</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Colao</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>De Block</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Gaztambide</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Kumar</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Seufert</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Casanueva</surname>
                      <given-names>FF</given-names>
                    </name>
                  </person-group>
                  <article-title>Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations</article-title>
                  <source>Pituitary</source>
                  <year>2014</year>
                  <volume>2013</volume>
                  <fpage>180</fpage>
                  <lpage>186</lpage>
                  <pub-id pub-id-type="doi">10.1007/s11102-013-0483-3</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
